AMENDMENTS TO THE CLAIMS

1. (previously presented): N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxy-pyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide covalently bonded to at least one acid, and the salts, solvates and prodrugs thereof.

2. (previously presented): The compound of Claim 1 or the salt, solvate or prodrug thereof, wherein the acid is covalently bonded via the 3-hydroxypyrrolidine group of the N-methyl-N-[(1 S)-1phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide.

3. (previously presented): The compound of Claim 1 or the salt, solvate or prodrug thereof, wherein the acid is a physiologically tolerated acid.

4. (previously presented): The compound of Claim 1 or the salt, solvate or prodrug thereof, wherein the acid is selected from the group consisting of carboxylic acids, hydroxycarboxylic acids and inorganic oxygen acids.

5. (previously presented): The compound of Claim 1 or the salt, solvate or prodrug thereof, wherein it contains at least one acid function which is capable of salt formation or an acid function which is in the form of a salt.

6. (previously presented): The compound of Claim 1 or the salt, solvate or prodrug thereof, wherein the acid is selected from the group consisting of dibasic carboxylic acids, monobasic hydroxycarboxylic acids and dibasic inorganic oxygen acids.

7. (previously presented): The compound of Claim 6 or the salt, solvate or prodrug thereof, wherein the monobasic hydroxycarboxylic acid is a sugar acid.

8. (previously presented): The compound of Claim 7 or the salt, solvate or prodrug thereof, wherein the sugar acid is glucuronic acid.

9. (previously presented): The compound of Claim 6 or the salt, solvate or prodrug thereof, wherein the dibasic inorganic oxygen acid is sulfuric acid.

10. (previously presented): The compound of Claim 1, selected from the group consisting of 6-(1-{[(2,2diphenylethanoyl)methylamino]phenylethyl} pyrrolidin-3-yloxy}-3,4,5-trihydroxytetrahydropyrarr-2-carboxylic acid, mono-{1[2-(diphenylacetyl-methylamino)-2phenylethyl]pyrrolidin-3-yl} sulfate and N-{2-[(3S)-3-acetoxy-1-pyrrolidinyl]-(1S)-1-phenylethyl}-2,2-diphenyl-N-methylacetamide, and salts, solvates, and prodrugs thereof.

11. (previously presented): The compound of Claim 1 and/or a salt, solvate or prodrug thereof as medicament.

Claims 12-18 (canceled)

19. (previously presented): A method for manufacture of a pharmaceutical composition, comprising:

formulating ingredients of the composition, wherein the ingredients comprise one or more compounds according to Claim 1, or a salt, solvate, or prodrug thereof, and one or more further compounds selected from excipients and adjuvants;

mixing the ingredients to homogeneity; and

preparing the mixture in a form suitable for administration to patients.

20. (previously presented): Pharmaceutical composition, wherein it comprises at least one compound, salt, solvate, or prodrug according to Claim 1.

21. (previously presented): Pharmaceutical composition according to Claim 20, wherein it comprises at least one further pharmaceutical active ingredient selected from the group consisting of appetite suppressants, vitamins, diuretics, and antiphlogistics.

22. (previously presented): Pharmaceutical composition according to Claim 21, wherein the further active ingredient is selected from phenylpropanolamine, cathine, sibutramine, amfepramone, ephedrine and norpseudoephedrine.

23. (currently amended): Process for the preparation of a compound of Claim 1 or a salt thereof, in which

a) a compound of the formula II



II

in which

L^1 is H or a metal ion;

b) is reacted with a compound of the formula III

$$R^1\text{-}L^2 \qquad \text{III}$$

in which

L^2 is a leaving group, and

R^1 is selected from substituted or unsubstituted acyl radicals having from 1 to 12 carbon atoms, alkyl radicals derived from polyhydroxymonocarboxylic acids by removal of a hydroxyl group, sulfonic acid groups, phosphonic acid groups and nitro groups, and if

R^1 ~~further comprises~~ is further selected from one or more functional groups selected from hydroxyl groups and acid groups, the functional group is optionally protected by a protecting group,

c) any protecting groups present are cleaved off, if desired the compound of the formula I is isolated, and optionally

d) the resultant compound of the formula I is converted into one of its salts by treatment with an acid or base, and, if desired, the salt is isolated.

24. (previously presented): A pharmaceutical composition comprising the compound of claim 10, or a salt, solvate, and prodrug thereof.